Left Ventricular Assist Device Market By Product Type (Controller, Heart Pump, Batteries, Wires); By Therapy (Destination Therapy, Bridge-to-Recovery [BTR] Therapy, Bridge-to-Transplant [BTT] Therapy, Bridge-to-Candidacy [BTC] Therapy); By Indication (Congestive Heart Failure, Familial Arrhythmias, Advanced Heart Failure, Congenital Heart Disease, Cardiac Arrest, Myocarditis, Cardiomyopathies, Others); By End User (Hospitals, Specialty Clinics, Cardiac Catheterization Laboratories, Others); By Geography, Segment revenue estimation, Forecast, 2024–2032.

The left ventricular assist device market was worth USD 1.3 billion in 2023 and will be worth USD 2.78 billion by 2030, growing at a CAGR of 10% during the forecast period.

 

A Left Ventricular Assist Device (LVAD) is a mechanical pump implanted adjacent to and in continuity with the apex of the left ventricle and the ascending aorta. LVADs have been used for thirty years, with indications of use as BTT to help the sick patient improve his/her quality of life while waiting for a possible heart transplant.

 

DT has experienced significant growth and has become the dominating LVAD in the US and Germany in Europe’s largest LVAD market in less than a decade. Despite indications there are more than 100,000 LVAD implantations every year in the US and Europe, such implants have become an established therapy, with approximately 8000 implants annually.

 

Market Dynamics

One major influence on the growing demand for LVAD is the rising incidences of heart failure around the world. As per the World Health Organization, cardiovascular diseases (CVDs) claim an estimated 17.9 million lives annually and are the world's leading cause of mortality. Heart failure (HF) affects over 6.7 million Americans over the age of 20, and its prevalence is predicted to increase to 8.7 million by 2030, 10.3 million by 2040, and 11.4 million by 2050. This rising occurrence has increased customer needs for enhanced treatment therapy such as LVADs, including mechanical support in heart failure. For example, the HeartMate 3 LVAD is well accepted because of higher hem compatibility and lower frequency of adverse events. Clinical trials have shown that patients who receive HeartMate 3 have better survival and lower quality of life than those who receive only medical treatment. Recent advancements in this field have targeted healthy adults and older children, with the HeartMate 3 receiving regulatory clearance for use in pediatric patients. This approval is significant in establishing the device's safety and efficiency in a more diverse population, increasing its application in practice. The increasing rates of HF have greatly driven LVAD market growth, with such developments as HeartMate 3 helping to address treatment gaps for HF patients.

 

A major constraint in the LVAD industry is the cost of implantation and maintenance. For instance, LVAD therapy costs, which range from the gadget to surgery alongside other post-operation intricacies, can go up to $200,000 per patient. High LVAD costs exclude many consumers, especially in areas with limited healthcare funding and for those with inadequate insurance. However, ongoing efforts aim to lower the price of LVADs in the future.

 

One of the major opportunities for growth in the LVAD market is the use of AI and ML in product design and implementation to improve the device and patient conditions. For example, proper sensor less control schemes for implantable heart pumps using real-time deep convolutional neural networks have been proposed for physiological control without further pressure or flow measurements. The following development may result in enhanced LVADs with fewer adverse effects and higher patients’ quality of life among those suffering from heart failure. A prospect of further evolution in LVAD technology can be enlisted in continuous advancement in artificial intelligence control systems.

 

Market Segmentation

Product Type:

• Controller

• Heart Pump

• Batteries

• Wires

 

Therapy:

• Destination Therapy

• Bridge-to-Recovery (BTR) Therapy

• Bridge-to-Transplant (BTT) Therapy

• Bridge-to-Candidacy (BTC) Therapy

 

Indication:

• Congestive Heart Failure

• Familial Arrhythmias

• Advanced Heart Failure

• Congenital Heart Disease

• Cardiac Arrest

• Myocarditis

• Cardiomyopathies

• Others

 

End User:

• Hospitals

• Specialty Clinics

• Cardiac Catheterization Laboratories

• Others

 

By Region

North America

• US

• Mexico

• Canada

• Rest of North America

 

Europe

• Switzerland

• Russia

• France

• Germany

• U.K

• Finland

• Turkey

• Netherlands

• Belgium

• Spain

• Italy

• Rest of Europe

 

Asia Pacific

• India

• China

• South Korea

• Japan

• Singapore

• Thailand

• Indonesia

• Malaysia

• Philippines

• Australia

• Rest of Asia-Pacific

 

LAMEA

• Brazil

• Argentina

• Uruguay

• Saudi Arabia

• Rest of LAMEA

 

On the basis of product type, Destination Therapy held a dominant position in the market with a significant revenue share. Destination Therapy has become an overall market segment for LVADs among patients not candidates for heart transplantation. This therapy has been developed for patients suffering from advanced heart failure who are not fit to be transplanted with a healthy heart and who require life-long Meadows Circulatory Support. The research literature affirms Destination Therapy patients report better survival and quality of life. Some devices as HeartMate II and HeartMate 3 are known for having good results when used in long-term support situations. Newer, fully implantable LVAD devices like HeartMate 3 have improved the patients’ mobility and lowered infection rates, making destination therapy more appealing. Moreover, such regulatory authorities as the US Food and Drug Administration have broadened indications for some types of LVADs, which has caused this segment′s availability for a larger amount of patients, for example, Destination Therapy. These factors explain the rising role of Destination Therapy in the scope of LVAD due to the versatility and innovation of the devices.

 

 

North America, especially the United States, held a dominant position in the market with a significant revenue share. This leadership is attributed to the high incidence of heart failure, a sophisticated system of health, and relatively high spending on research and development of health products. For instance, the U.S. Food and Drug Association FDA has endorsed numerous LVADs implemented in most healthcare facilities, including the HeartMate 3. Some new advancements involve the US Food and Drug Administration authorizing HeartMate 3 LVAD for pediatric use, allowing young patients to benefit from the technology. Such expansion further cements the region’s focus on LVAD technological development and bettering outcomes for patients.

 

Key Players

• Abbott Laboratories

• Medtronic plc

• Abiomed Inc.

• Jarvik Heart Inc.

• CorWave SA

• LivaNova PLC

• Magenta Medical

• CardiacAssist Inc.

• HeartWare International

• SynCardia Systems LLC

• Ventracor Limited

• Berlin Heart GmbH

• Novacor Medical Corp

• Thoratec Corporation

• ReliantHeart Inc.

 

Recent Development

• In August 2024, Abbott's HeartMate 3 left ventricular assist device now has a label update approved by the US Food and Drug Administration (FDA) that does away with the necessity for aspirin as part of standard patient care. Only Abbott HeartMate 3 heart pump patients are eligible for the label update. The label modification has also received approval from regulatory agencies in Canada and Europe.

 

• In August 2024, Cadrenal Therapeutics, Inc., a biopharmaceutical company, revealed that it will hold a Type-B meeting with the U.S. Food and Drug Administration (FDA) in early September to discuss its clinical trial for warfarin in patients with LVAD. Tecarfarin is a late-stage, next-generation oral Vitamin K Antagonist (VKA) and reversible anticoagulant (blood thinner) intended to prevent heart attacks, strokes, and blood clot deaths in patients with implanted cardiac devices and those with rare cardiovascular conditions.